Results 241 to 250 of about 49,034 (266)
Some of the next articles are maybe not open access.
Management of thrombotic thrombocytopenic purpura
Transfusion Clinique et Biologique, 2017Daily therapeutic plasma exchange (TPE) transformed the historically fatal prognosis of acquired, anti-ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura (TTP), leading to the current overall survival rates of >80%. However, relapses occur in up to 40% of patients and refractory disease with fatal outcomes still occurs, typically within the
openaire +2 more sources
Thrombotic Thrombocytopenic Purpura Today
Hospital Practice, 1999Thrombotic thrombocytopenic purpura (TTP) usually responds to plasma exchange and plasma infusion. However, until recently, it was not clear how the treatment works. New understanding of the pathophysiology of TTP has clarified that issue and suggested new therapies that may eliminate plasma infusion and its risks.
openaire +2 more sources
Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department
Journal of Emergency Medicine, 2021Brit Long, Michael Gottlieb
exaly
Thrombotic thrombocytopenic purpura
The Hematology Journal, 2004Lämmle B +4 more
openaire +3 more sources
Duodenal Thrombotic Thrombocytopenic Purpura
Clinical Gastroenterology and Hepatology, 2007David J, Owens, Barbara, Jung
openaire +2 more sources
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
Nature, 2001G. Levy +18 more
semanticscholar +1 more source
<p>Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura</p>
Drug Design, Development and Therapy, 2019Tugrul Elverdi, Ahmet Emre Eşkazan
exaly